Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 7/20 | 0.38 |
| ▸ | FAAH | O00519 | 6/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.38 |
| ▸ | GBA1 | P04062 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | G6PD | P11413 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4602084 | 0.97 | MGLL (0.40) | MGLLFAAHPTGS1PTGS2GBA1 | |
| SCHEMBL10337687 | 0.95 | GAA (0.35) | MGLLFAAHPTGS1PTGS2GBA1 | |
| SCHEMBL4601323 | 0.90 | MGLL (0.40) | MGLLFAAHPTGS1PTGS2GBA1 | |
| SCHEMBL17767287 | 0.74 | MGLL (0.42) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL4602397 | 0.74 | FAAH (0.39) | MGLLFAAHALDH1A1GAAMEN1 | |
| SCHEMBL6779927 | 0.73 | MGLL (0.50) | MGLLFAAHPTGS1PTGS2GBA1 | |
| SCHEMBL13837373 | 0.73 | MGLL (0.46) | MGLLFAAHPTGS1PTGS2GBA1 | |
| SCHEMBL2905468 | 0.71 | MGLL (0.53) | MGLLFAAHPTGS1PTGS2GBA1 | |
| SCHEMBL9318984 | 0.71 | MGLL (0.49) | MGLLFAAHPTGS1PTGS2GBA1 | |
| SCHEMBL7184113 | 0.70 | MGLL (0.43) | MGLLFAAHPTGS1PTGS2GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9085539-B2 | Cyclic N,N′-diarylthiourea—androgen receptor antagonist, anti breast cancer composition and use thereof | R-PHARM OVERSEAS INC. | 2015-07-21 | — | — | US | disclosed |
| CN-102482231-B | Sulfonic amide and sulfoximine-substituted diaryl-dihydropyrimidinones and usage thereof | BAYER IP GMBH | 2014-12-17 | — | — | CN | disclosed |
| EP-2767531-A1 | Cyclic n,n'-diarylthioureas and n,n'-diarylureas as androgen receptor antagonists, anti-cancer agent, method for producing and using same | Ivachtchenko, Alexandre Vasilievich (US) | 2014-08-20 | — | — | EP | disclosed |
| US-8691817-B2 | Sulfonic amide and sulfoximine-substituted diaryl-dihydropyrimidinones and usage thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-04-08 | — | — | US | disclosed |
| US-20130252992-A1 | CYCLIC N,N'-DIARYLTHIOUREA - ANDROGEN RECEPTOR ANTAGONIST, ANTI BREAST CANCER COMPOSITION AND USE THEREOF | R-PHARM OVERSEAS INC. | 2013-09-26 | — | — | US | disclosed |
| EP-2597086-A1 | CYCLIC N,N'-DIARYLTHIOUREAS AND N,N'-DIARYLUREAS AS ANDROGEN RECEPTOR ANTAGONISTS, ANTI-CANCER AGENT, METHOD FOR PRODUCING AND USING SAME | Ivachtchenko, Alexandre Vasilievich (RU) | 2013-05-29 | — | — | EP | disclosed |
| US-20130116269-A1 | CYCLIC N,N'-DIARYLTHIOUREAS AND N,N'-DIARYLUREAS - ANDROGEN RECEPTOR ANTAGONISTS, ANTICANCER AGENT, METHOD FOR PREPARATION AND USE THEREOF | R-PHARM OVERSEAS INC. | 2013-05-09 | — | — | US | disclosed |
| CN-102482231-A | Sulfonic amide and sulfoximine-substituted diaryl-dihydropyrimidinones and usage thereof | Bayer Pharma AG | 2012-05-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116269-A1 | CYCLIC N,N'-DIARYLTHIOUREAS AND N,N'-DIARYLUREAS - ANDROGEN RECEPTOR ANTAGONISTS, ANTICANCER AGENT, METHOD FOR PREPARATION AND USE THEREOF | AR, NR5A1, GNRHR | MGLL 4387/4885FAAH 1033/4885PTGS1 413/4885 |
| US-20130252992-A1 | CYCLIC N,N'-DIARYLTHIOUREA - ANDROGEN RECEPTOR ANTAGONIST, ANTI BREAST CANCER COMPOSITION AND USE THEREOF | AR, NR5A1, CYP19A1 | MGLL 3975/4885FAAH 647/4885PTGS1 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.